Why invest
Our vision is to make MOB-015, launched in Sweden and Norway under the brand name Terclara®, the leading nail fungus treatment globally, and to build a specialty pharmaceutical company with our own sales in the U.S. and sales through partners in other markets.
World-leading anti-fungal effect
- 76% of the patients became fungus-free in two phase 3 studies that included over 800 patients
- MOB-015 is a topical formulation of terbinafine. 1000 times lower concentration of terbinafine in the blood compared to oral treatment.
- Strong premium position from true competitive advantage: Targeting category leadership with USD 250-500m potential global product sales
Strong commercial partners in place
Europa
Scandinavia
Canada
Israel
Market leader in nail fungus
- Terclara® became the market leader in Sweden and Norway instantly after starting consumer marketing
- National marketing authorization approvals received in 13 European countries, whereof 7 granted OTC status.
- Builds on previous successes with the first-generation product Kerasal Nail®/Nalox®, which was sold for 1.4 billion SEK
Significant events during the latest quarter
- Moberg Pharma and Karo Healthcare enter exclusive license agreement for MOB-015/Terclara® in Europe. The agreement comprises 19 European markets, enabling a coordinated launch across all key EU markets under the leading global antifungal brand Lamisil®.
- Norway: Terclara® launch nominated for “Launch of the Year” by the pharmacy chains Apotek 1 and Alliance Healthcare Sales data remain strong with 47% market share in Sweden and 37% in Norway for the third quarter
- Extraordinary General Meeting on September 29 resolved to expand the Board of Directors with two members, Fredrik Blom and Mona Zhang, and to revoke the authorization to issue shares, as the company is well-capitalized and does not foresee a need to utilize the authorization.
Share Price
Calendar
17-02-2026
Latest Press Releases